C92.02

HCC Category Mapping

What This Code Means

An acute blood cancer of myeloid cells that has returned after a period of remission.

Coding Tips

• •Document must clearly indicate the cancer has recurred after prior remission
• •Distinguish from initial diagnosis by confirming previous remission status in patient history

Clinical Significance

Acute myeloblastic leukemia in relapse indicates return of AML after previously achieving remission, which is one of the most serious clinical scenarios in hematologic oncology. Relapsed AML carries a poor prognosis, with long-term survival rates of 10-30% depending on the duration of first remission and molecular features at relapse. Treatment typically involves intensive salvage chemotherapy followed by allogeneic stem cell transplantation when feasible.

Documentation Requirements

• ✓Documentation must confirm prior complete remission and current evidence of relapse (rising blast count, new extramedullary disease).
• ✓Updated cytogenetic and molecular testing at relapse is essential as clonal evolution is common and may reveal new therapeutic targets or adverse features.
• ✓Duration of first remission, prior treatment regimens, and transplant candidacy assessment must be documented.

Commonly Confused Codes